Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective

Published:2022-06-01 Issue:16 Volume:40 Page:1721-1731
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Hertz Daniel L.¹^ORCID,McShane Lisa M.²^ORCID,Hayes Daniel F.³^ORCID

Affiliation:

1. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI

2. Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD

3. Stuart B. Padnos Professor of Breast Cancer Research, University of Michigan Rogel Cancer Center, Ann Arbor, MI

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.21.02209

Reference76 articles.

1. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

2. Clinical utility of genomic sequencing: a measurement toolkit

3. Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity;Pharmacogenomics;2024-08-02

2. Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms;Pharmacogenetics and Genomics;2024-02-08

3. Systemic inflammation and cancer-related frailty: shifting the paradigm toward precision survivorship medicine;ESMO Open;2024-01

4. Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study;Pharmacological Research;2023-11

5. Checkpoint inhibitors and anti-angiogenic agents: a winning combination;British Journal of Cancer;2023-09-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3